Role of the basolateral nucleus of the amygdala in the formation of a phobia

Neuropsychopharmacology

Volumn 19, Issue 5, 1998, Pages 397-405

  File, Sandra E ^a   Gonzalez, Luis E ^a   Gallant, Rachael ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Amygdala; Anxiety; Benzodiazepines; Emotional memory; Phobia; Plus maze

Indexed keywords

CHLORDIAZEPOXIDE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY; ARTICLE; CONTROLLED STUDY; HISTOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MAZE TEST; MEMORY; NONHUMAN; PHOBIA; PRIORITY JOURNAL; RAT;

AMYGDALA; ANIMALS; ANTI-ANXIETY AGENTS; CHLORDIAZEPOXIDE; LIDOCAINE; MALE; MOTOR ACTIVITY; PHOBIC DISORDERS; RATS;

EID: 0032210989     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00035-9     Document Type: Article

References (31)

1. Davis M. The role of the amygdala in fear and anxiety. Ann Rev Neurosci. 15:1992;353-375.
2. Dawson G.R., Crawford S.P., Stanhope K.J., Iversen S.D., Tricklebank M.D. One-trial tolerance to the effects of chlordiazepoxide on the elevated plus-maze may be due to locomotor habituation, not repeated drug exposure. Psychopharmacology. 113:1994;570-572.
3. Everitt B.J., Robbins T.W. Amygdala-ventral striatal interaction and reward related processes. Aggleton J.P. The Amygdala. Neurobiological Aspects of Emotion, Memory, and Mental Dysfunction:1992;401-429 Wiley-Liss, New York.
4. Fernandes C., File S.E. The influence of open-arm ledges and maze experience in the elevated plus-maze. Pharmacol Biochem Behav. 54:1996;31-40.
5. File S.E. One-trial tolerance to the anxiolytic effects of chlordiazepoxide in the plus-maze. Psychopharmacology. 100:1990;281-282.
6. File S.E. The biological basis of anxiety. Meltzer H.Y., Nerozzi D. Current Practices and Future Developments in the Pharmacotherapy of Mental Disorders. 1991;159-165 Ex Medica, Amsterdam.
7. File S.E. The interplay of learning and anxiety in the elevated plus-maze. Behav Brain Res. 58:1993;199-202.
8. 1A receptor ligands in dorsal raphe and ventral hippocampus. Pharmacol Biochem Behav. 54:1996;123-128.
9. File S.E., Zangrossi H. "One-trial tolerance" to the anxiolytic actions of benzodiazepines in the elevated plus-maze, or the development of a phobic state? Psychopharmacology. 110:1993;240-244.
10. File S.E., Andrews N., Hogg S. New developments in animal tests of anxiety. Westenberg H.G.M., Den Boer J.A., Murphy D.L. Advances in the Neurobiology of Anxiety Disorders. 1996;61-79 Wiley, Chichester, UK.
11. File S.E., Mabbutt P.S., Hitchcott P. Characterization of the phenomenon of "one-trial tolerance" to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze. Psychopharmacology (Berlin). 102:1990;98-101.
12. File S.E., Zangrossi H., Viana M., Graeff F.G. Trial 2 in the elevated plus-maze. A different form of fear? Psychopharmacology. 111:1993;494.
13. Fredrikson M., Wik G., Greitz T., Eriksson L., Stone-Elander S. Regional cerebral blood flow during experimental phobic fear. Psychophysiology. 30:1993;127-131.
14. Fredrikson M., Wik G., Annas P., Ericson K., Stone-Elander S. Functional neuroanatomy of visually elicited simple phobic fear. Additional data and theoretical analysis Psychophysiology. 32:1995;43-48.
15. Gonzalez L.E., File S.E. A five minute experience in the elevated plus-maze alters the state of the benzodiazepine receptor in the dorsal raphe nucleus. J Neuroscience. 17:1997;1505-1511.
16. Killcross S., Robbins T.W., Everitt B.J. Different types of fear-conditioned behavior mediated by separate nuclei within amygdala. Nature. 388:1997;377-380.
17. Klein D.F. Anxiety reconceptualized. Klein D.F., Rabkin J. Anxiety. New Research and Changing Concepts:1981;235-263 Raven Press, New York.
18. LeDoux J. The Emotional Brain. 1996;Simon & Schuster, New York.
19. McGaugh J.L. Emotional activation, neuromodulatory systems, and memory. Schacter D.L., Coyle J.T., Mesulam M.-M., Sullivan L.E. Memory Distortion. How Minds, Brains, and Societies Reconstruct the Past:1995;255-273 Harvard University Press, Cambridge, MA.
20. McGaugh J.L., Cahill L., Roozendall B. Involvement of the amygdala in memory storage. Interaction with other brain systems Proc Natl Acad Sci USA. 93:1996;13508-13514.
21. Marks I.M. Fears, Phobias, and Rituals. 1987;Oxford University Press, New York.
22. Parent M.B., McGaugh J.L. Post-training infusion of lidocaine into the amygdala basolateral complex impairs retention of inhibitory avoidance training. Brain Res. 661:1994;97-103.
23. Paxinos G., Watson C.H. The Rat Brain in Stereotaxic Coordinates. 1986;Academic, London.
24. Pellow S., Chopin P., File S.E., Briley M. Validation of open- closed-arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Meth. 14:1985;149-167.
25. Pesold C., Treit D. The septum and amygdala differentially mediate the anxioltyic effects of benzodiazepines. Brain Re. 638:1994;295-301.
26. Pesold C., Treit D. The central and basolateral amygdala differentially mediate the anxiolytic effects of benzodiazepines. Brain Res. 671:1995;213-221.
27. Rodgers R.J., Johnson N.J.T. Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol Biochem Behav. 52:1995;297-303.
28. Rodgers R.J., Shepherd J.K. Influence of prior maze experience on behavior and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice. Psychopharmacology. 113:1993;237-242.
29. Rodgers R.J., Lee C., Shepherd J.K. Effects of diazepam on behavioral and antinociceptive responses to the elevated plus-maze in male mice depend upon treatment regimen and prior maze experience. Psychopharmacology. 106:1992;102-110.
30. Treit D., Menard J., Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav. 44:1993;463-469.
31. Tyrer P. Choice of treatment in anxiety. Tyrer P. Psychopharmacology of Anxiety. 1989;254-282 Oxford Medical Publications, Oxford, UK.